{"organizations": [], "uuid": "814f19aa191ca64bb10dadb59562bd7e472ad4e4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-psivida-corp-announces-transformat/brief-psivida-corp-announces-transformative-acquisition-of-icon-bioscience-idUSASC09U27", "country": "US", "domain_rank": 408, "title": "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T23:32:00.000+03:00", "replies_count": 0, "uuid": "814f19aa191ca64bb10dadb59562bd7e472ad4e4"}, "author": "", "url": "https://www.reuters.com/article/brief-psivida-corp-announces-transformat/brief-psivida-corp-announces-transformative-acquisition-of-icon-bioscience-idUSASC09U27", "ord_in_thread": 0, "title": "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience", "locations": [], "entities": {"persons": [{"name": "psivida", "sentiment": "none"}], "locations": [{"name": "psivida", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "brief-psivida corp", "sentiment": "negative"}, {"name": "icon bioscience reuters", "sentiment": "none"}, {"name": "eyepoint pharmaceuticals inc", "sentiment": "none"}, {"name": "psivida corp", "sentiment": "none"}, {"name": "psivida", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28, 2018 / 8:35 PM / Updated 5 minutes ago BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience Reuters Staff 2 Min Read \nMarch 28 (Reuters) - pSivida Corp: \n* PSIVIDA CORP ANNOUNCES TRANSFORMATIVE ACQUISITION OF ICON BIOSCIENCE INC AND GROWTH CAPITAL FINANCING WITH ESSEX WOODLANDS HEALTHCARE PARTNERS â€“ COMPANY WILL REBRAND AS EYEPOINT PHARMACEUTICALS INC \n* PSIVIDA CORP - SWK HOLDINGS WILL PROVIDE UP TO $20 MILLION IN DEBT FINANCING \n* PSIVIDA CORP - DEAL FOR APPROXIMATELY $60.5 MILLION \n* PSIVIDA CORP - PSIVIDA CORP. WILL REBRAND AND CHANGE ITS NAME TO EYEPOINT PHARMACEUTICALS INC. \n* PSIVIDA CORP - ENTERED INTO A FINANCIAL AGREEMENT WITH EW HEALTHCARE PARTNERS \n* PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE EQUITY INVESTMENTS IN PSIVIDA \n* PSIVIDA CORP - WILL USE FUNDS TO FINANCE ICON ACQUISITION AND PREPARE FOR COMMERCIAL LAUNCHES OF DEXYCU \n* PSIVIDA CORP - IF APPROVED, PSIVIDA EXPECTS TO LAUNCH DURASERT IN U.S. IN FIRST HALF OF 2019 \n* PSIVIDA CORP - PSIVIDA PLANS TO LAUNCH DEXYCU IN U.S. IN FIRST HALF OF 2019 \n* PSIVIDA CORP - EW HEALTHCARE PARTNERS AND A THIRD PARTY INVESTOR WILL MAKE AN EQUITY INVESTMENT IN PSIVIDA FOR UP TO ABOUT $60.5 MILLION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-28T23:32:00.000+03:00", "crawled": "2018-03-28T23:50:57.003+03:00", "highlightTitle": ""}